Stem cells injected into heart arteries may help repair damage after a heart attack

NCT ID NCT05724576

Terminated Disease control Sponsor: Taiwan Bio Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This early-phase trial tests whether a single dose of donor stem cells (OmniMSC-AMI) given directly into the heart arteries is safe for people who have just had a major heart attack. The study enrolls adults aged 20–80 with a specific type of heart attack (anterior STEMI) who are treated within 6 hours. Researchers will monitor side effects and measure heart function over time to see if the stem cells might help the heart pump better.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: OmniMSC-AMI (donor bone marrow stem cells)
What this could lead to: If safe and effective, this approach could help repair heart muscle after a heart attack and improve pumping function.
What could go wrong: This is a very early, small safety trial with only 10 people. It is not designed to prove the treatment works, and stem cell therapies carry risks like inflammation or arrhythmia.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SAFETY ISSUES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SAFETY ISSUES

Contacts and locations

Show contact details

Locations

Kaohsiung Chang Gung Memorial Hospital

Kaohsiung City, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.